Diagnostic Performance of PET or PET/CT with Different Radiotracers in Patients with Suspicious Lung Cancer or Pleural Tumours according to Published Meta-Analyses

Table 1

Characteristics and main findings of included meta-analyses on the diagnostic performance of PET or PET/CT with different radiotracers for evaluation of patients with suspicious lung cancer or pleural tumours.

Topic	Authors	Year	Articles included	Patients (p) or lesions (l) included	Sensitivity (95% CI)	Specificity (95% CI)	LR+ (95% CI)	LR−(95% CI)	DOR (95% CI)
^18F-FDG PET or PET/CT for lung cancer screening	Chien et al. [4]	2013	4	9199 (p)	83% (75–89)	91% (86–95)	NR	NR	NR
Characterization of SPNs by single time point ^18F-FDG PET or PET/CT	Zhang et al. [14]	2013	8	415 (p)	77% (71.9–82.3)	59% (50.6–66.2)	1.97 (1.32–2.93)	0.37 (0.29–0.49)	6.39 (3.4–12)
				430 (l)
	Deppen et al. [5]	2014	70	8511 (l)	89% (86–91)	75% (71–79)	NR	NR	NR
	Wang et al. [6]	2015	4	1330 (p)	98.7%	58.2%	NR	NR	NR
	Li et al. [16]	2015	7	301 (p)	92% (86–95)	50% (41–58)	2.01 (1.38–2.93)	0.17 (0.10–0.29)	10.72 (5.51–20.87)
	Wang et al. [17]	2016	10	351 (p)	89%	66%	NR	NR	NR
	Ruilong et al. [7]	2017	12	1297 (p)	82% (76–87)	81% (66–90)	4.3 (2.3–7.9)	0.22 (0.16–0.3)	17.6 (8.2–37.7)
				1301 (l)
	Li et al. [8]	2018	20	1557 (p)	89% (87–91)	70% (66–73)	3.33 (2.35–4.71)	0.18 (0.13–0.25)	22.43 (12.5–40.1)
	Divisi et al. [9]	2018	12	1463 (p)	81.9% (79.4–84.3)	62.4% (58.2–66.5)	2.19 (1.95–2.44)	0.29 (0.25–0.33)	7.05 (5.5–8.9)
	Jia et al. [10]	2019	23	NR	89% (85–92)	78% (66–86)	3.97 (2.57–6.13)	0.15 (0.10–0.20)	24 (12.7–45.5)
	Basso Dias et al. [11]	2019	5	735 (p)	78% (70–84)	81% (72–88)	4.1 (2.6–6.5)	0.8 (0.19–0.40)	15 (7–32)
Characterization of SPNs by dual time point ^18F-FDG PET or PET/CT	Lin et al. [12]	2012	11	778 (p)	NR	NR	NR	NR	NR
	Barger and Nandalur [13]	2012	10	816 (p)	85% (82–89)	77% (72–81)	2.7 (1.4–5.2)	0.26 (0.14–0.49)	11 (3.8–32.2)
				890 (l)
	Zhang et al. [14]	2013	8	415 (p)	79% (74–84)	73% (65–79)	2.61 (1.96–3.47)	0.29 (0.21–0.41)	10.25 (5.8–18.1)
				430 (l)
	Zhao et al. [15]	2016	13	962 (p)	80% (76–84)	75% (71–79)	2.57 (1.54–4.29)	0.28 (0.16–0.5)	10.01 (3.8–26.2)
Characterization of SPNs by ^18F-FLT PET or PET/CT	Li et al. [16]	2015	7	301 (p)	81% (74–87)	70% (61–77)	4.01 (1.62–9.88)	0.27 (0.20–0.37)	12.58 (6.8–23.2)
	Wang et al. [17]	2015	17	548 (p)	80% (74–85%)	82% (74–88)	NR	NR	NR
Characterization of pleural lesions by ^18F-FDG PET or PET/CT	Treglia et al. [18]	2014	11	NR	95% (92–97)	82% (76–88)	5.3 (2.4–11.8)	0.09 (0.05–0.14)	74 (34–161)
	Treglia et al. [19]	2014	8	360 (p)	86% (80–91)	80% (73–85)	3.7 (2.8–4.9)	0.18 (0.09–0.34)	27 (13–56)
	Porcel et al. [20]	2015	11	NR	91% (86–94)	67% (56–77)	2.83 (2.04–3.98)	0.14 (0.08–0.22)	22 (10.2–41.7)

¹⁸F-FDG = fluorine-18 fluorodeoxyglucose; ¹⁸F-FLT = fluorine-18 fluorothymidine; LR+ = positive likelihood ratio; LR− = negative likelihood ratio; DOR = diagnostic odds ratio; 95% CI = 95% confidence interval; NR = not reported; SPNs = solitary pulmonary nodules; PET = positron emission tomography; CT = computed tomography.